BDBM387266 N-(5′- (4-Ethyl-5-oxo-4,5- dihydro-1,3,4- oxadiazol-2-yl)-2′- methyl-[1,1′- biphenyl]-4-yl)-2,6- difluorobenzamide::US10292981, Example 34
SMILES: CCn1nc(oc1=O)-c1ccc(C)c(c1)-c1ccc(NC(=O)c2c(F)cccc2F)cc1
InChI Key: InChIKey=OWPMRXOYWPQBNY-UHFFFAOYSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Interleukin-2 (Homo sapiens (Human)) | BDBM387266 (N-(5′- (4-Ethyl-5-oxo-4,5- dihydro-1,3,4- ...) | PDB MMDB KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company | Assay Description Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells... | Bioorg Med Chem Lett 18: 1958-62 (2008) BindingDB Entry DOI: 10.7270/Q2D50Q8B | |||||||||||
More data for this Ligand-Target Pair |